SEC Form 4 · accession 0001209191-15-074103
ALDER BIOPHARMACEUTICALS INC · ALDR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark James Litton
Officer — Chief Business Officer
Period of report
Oct 1, 2015
Accepted (ET)
Oct 5, 2015 · 6:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001423824
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Oct 1, 2015 | S | 6,940 | $32.2233 | D | 73,479 | D | |
| Common StockF1,F3 | Oct 1, 2015 | S | 560 | $32.8082 | D | 72,919 | D | |
| Common Stock | holding | — | — | — | 30,000 | I | Held in trust for the benefit of Reporting Person's minor child | |
| Common Stock | holding | — | — | — | 30,000 | I | Held in trust for the benefit of Reporting Person's minor child | |
| Common Stock | holding | — | — | — | 30,000 | I | Held in trust for the benefit of Reporting Person's minor child |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2014.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.71 to $32.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.74 to $32.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4.